Dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway is frequently observed across a wide range of cancers and contributes to uncontrolled cell proliferation, enhanced ...
The PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM inhibition with ET plus CDK4/6i after progression may ...
The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a ...
The results were striking: "Obese mice fed a high-fat diet and treated with the mTOR inhibitor rapamycin lost significant amounts of weight, which—similar to leptin treatment in leptin-sensitive ...
BM-3103 is a first-in-class topical mTOR inhibitor that promotes autophagy to clear mutant keratin aggregates in epidermolysis bullosa simplex. The Food and Drug Administration (FDA) has granted Fast ...
Managing the side effects in patients being treated for metastatic breast cancer can be challenging. Recently, Marla D. Lipsyc-Sharf, MD, a breast medical oncologist and health sciences clinical ...
Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...
Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life. The PAM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results